Versartis (VSAR) Completes Phase 3 VELOCITY Trial Enrollment
Tweet Send to a Friend
Versartis, Inc. (Nasdaq: VSAR) announced the completion of enrollment in the Phase 3 VELOCITY trial of somavaratan in pediatric GHD ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE